---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-014684"
form_type: "8-K"
ticker: null
cik: "0001496671"
company_name: "Calithera Biosciences, Inc."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:26:14.588224+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Calithera to dissolve; Nasdaq delisting effective Feb 2, 2023 after 'public shell' determination

## Summary
- Board approved dissolution and liquidation plan on Jan 9, 2023, subject to stockholder approval.
- Company discontinuing all clinical programs and terminating most employees by end of Q1.
- Nasdaq notified Calithera it is a 'public shell'; company will not appeal the determination.
- Trading of common stock to be suspended as of Feb 2, 2023; Nasdaq to file Form 25-NSE to delist.

## SEC filing metadata
- accession: 0001193125-23-014684
- form_type: 8-K
- cik: 0001496671
- company_name: Calithera Biosciences, Inc.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496671/000119312523014684/0001193125-23-014684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496671/000119312523014684/d181884d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-014684
- JSON: https://secwatch.observer/filing/0001193125-23-014684.json
- Plain text: https://secwatch.observer/filing/0001193125-23-014684.txt

## Key facts
- Listing & Compliance Notices
  Calithera Biosciences, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5101
  source text: January 24, 2023, we received written notice from The Nasdaq Stock Market LLC, or Nasdaq, advising us that based upon Nasdaq’s review and pursuant to Listing Rule 5101, Nasdaq believes that we are a “public shell,” and that the continued listing of our securities is no longer warranted. We will not appeal Nasdaq’s determination. Therefore, we expect, based on Nasdaq’s written notice, that the trading of our common stock will be suspended as of the opening of business on February 2, 2023, and that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove our
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496671/000119312523014684/0001193125-23-014684-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.